Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Servier
Wake Forest University Health Sciences
University of Washington
Ohio State University Comprehensive Cancer Center
University of Kentucky
Sumitomo Pharma Co., Ltd.
Massachusetts General Hospital
University of Chicago
Dana-Farber Cancer Institute
Case Comprehensive Cancer Center
Stanford University
Wake Forest University Health Sciences
University of Southern California
Dartmouth-Hitchcock Medical Center
University of Pittsburgh
National Cancer Institute (NCI)
University of Pittsburgh
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Washington University School of Medicine
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center